Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 7/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 2/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL21931904 | 0.98 | MAPKAPK2 (0.37) | MAPKAPK2CHRNB2CHRNA4PTPN11GRM5 | |
| SCHEMBL31416583 | 0.83 | MAPKAPK2 (0.40) | MAPKAPK2CHRNB2GRM5CHRNA3 | |
| SCHEMBL21931902 | 0.72 | PIM1 (0.36) | MAPKAPK2GRM5 | |
| SCHEMBL7705836 | 0.71 | CHRNB4 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3HRH3 | |
| SCHEMBL29912977 | 0.69 | — | — | |
| SCHEMBL913739 | 0.69 | — | — | |
| SCHEMBL31274085 | 0.68 | MAPKAPK2 (0.37) | MAPKAPK2CHRNB2GRM5CHRNA3 | |
| SCHEMBL1560727 | 0.67 | — | — | |
| SCHEMBL30743728 | 0.67 | — | — | |
| SCHEMBL24818332 | 0.67 | MAPKAPK2 (0.33) | MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | INCYTE CORPORATION (US) | 2021-11-02 | — | — | US | disclosed |
| WO-2020102150-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION (US) | 2020-05-22 | — | — | WO | disclosed |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | INCYTE CORPORATION | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161838-B2 | Heterocyclic derivatives as PI3K inhibitors | PIK3CD, PIK3R5, PIK3CG | MAPKAPK2 164/4885CHRNB2 3767/4885CHRNA4 4271/4885 |
| US-20200148671-A1 | HETEROCYCLIC DERIVATIVES AS PI3K INHIBITORS | PIK3CD, PIK3R5, PIK3CG | MAPKAPK2 164/4885CHRNB2 3767/4885CHRNA4 4271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.